Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Model scores of the 29,894 trials active now.

Model score 33% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-12-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancercell lungsmall cellchemotherapyqt
  Phrases that lowered it: participantclinical studyplasmainvestigatororal
• Sponsor's past termination rate: 11.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 105 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 28.7% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 398 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 67.7% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 8846 (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 1153 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer NCT03088930 · started 2017 · scored riskier than 86% of active trials completed
• EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer NCT02183870 · started 2014 · scored riskier than 71% of active trials completed
• A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung NCT01154140 · started 2011 · scored riskier than 90% of active trials completed
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation NCT04427072 · started 2020 · scored riskier than 49% of active trials terminated
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) NCT02414139 · started 2015 · scored riskier than 55% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.